Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China. - OpacWWW

Tytuł:: Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.
Autorzy:: Feng L; Department of Hepatology, The First Hospital of Jilin University, Changchun, China.
Dong K; Department of Gastroenterology, Yantaishan Hospital, Shandong, China.
Zhang X; Department of Hepatology, The First Hospital of Jilin University, Changchun, China.
Ma B; Department of Hepatology, The First Hospital of Jilin University, Changchun, China.
Chen L; Department of Hepatology, The First Hospital of Jilin University, Changchun, China.
Yang Q; Department of Hepatology, The First Hospital of Jilin University, Changchun, China.
Chen Q; Department of Hepatology, The First Hospital of Jilin University, Changchun, China.
Wen X; Department of Hepatology, The First Hospital of Jilin University, Changchun, China.
Jin Q; Department of Hepatology, The First Hospital of Jilin University, Changchun, China.
Źródło:: PloS one [PLoS One] 2020 Nov 12; Vol. 15 (11), pp. e0242164. Date of Electronic Publication: 2020 Nov 12 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:: Autoantigens/*immunology
Immunoglobulin G/*immunology
Liver Cirrhosis, Biliary/*immunology
Mitochondrial Proteins/*immunology
Aged ; Autoantigens/blood ; Biomarkers/blood ; Female ; Humans ; Immunoglobulin G/blood ; Liver Cirrhosis, Biliary/pathology ; Male ; Middle Aged
References:: Intern Med. 1995 Jun;34(6):496-501. (PMID: 7549131)
J Immunol. 1987 May 15;138(10):3525-31. (PMID: 3571977)
Am J Gastroenterol. 2002 Apr;97(4):999-1002. (PMID: 12003438)
Semin Liver Dis. 2002 Aug;22(3):291-302. (PMID: 12360422)
N Engl J Med. 2005 Sep 22;353(12):1261-73. (PMID: 16177252)
Gastroenterology. 1980 Feb;78(2):236-46. (PMID: 7350046)
J Med Invest. 2017;64(1.2):7-13. (PMID: 28373632)
Hepatology. 1997 May;25(5):1090-5. (PMID: 9141422)
Gastroenterol Clin North Am. 2008 Jun;37(2):479-84, viii. (PMID: 18499032)
Hepatol Int. 2017 Nov;11(6):485-499. (PMID: 29164395)
Hepatology. 2009 Jul;50(1):291-308. (PMID: 19554543)
Lancet. 2015 Oct 17;386(10003):1565-75. (PMID: 26364546)
J Clin Immunol. 2007 Jul;27(4):378-87. (PMID: 17514501)
World J Gastroenterol. 2005 Sep 28;11(36):5706-9. (PMID: 16237770)
J Epidemiol. 2006 Jan;16(1):30-4. (PMID: 16369106)
Expert Rev Mol Diagn. 2016 Jun;16(6):697-705. (PMID: 26953925)
Scand J Gastroenterol. 2016;51(6):745-52. (PMID: 26776319)
Hepatology. 1997 Jan;25(1):6-11. (PMID: 8985257)
J Gastroenterol. 1999 Oct;34(5):607-12. (PMID: 10535489)
Immunol Res. 2017 Feb;65(1):299-306. (PMID: 27475095)
Dig Dis Sci. 2011 Sep;56(9):2750-7. (PMID: 21409375)
Baillieres Best Pract Res Clin Gastroenterol. 2000 Aug;14(4):601-13. (PMID: 10976017)
J Gastroenterol Hepatol. 2019 Jul;34(7):1236-1241. (PMID: 30365184)
Liver Int. 2008 Feb;28(2):233-9. (PMID: 18251980)
Clin Rev Allergy Immunol. 2012 Jun;42(3):288-97. (PMID: 21188646)
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):678-9. (PMID: 26553417)
Hepatology. 2016 Mar;63(3):930-50. (PMID: 26223498)
N Engl J Med. 1983 Jan 6;308(1):1-7. (PMID: 6847917)
Clin Dev Immunol. 2004 Jun;11(2):129-33. (PMID: 15330448)
Aliment Pharmacol Ther. 2003 Jan;17(1):17-27. (PMID: 12492729)
Substance Nomenclature:: 0 (Autoantigens)
0 (Biomarkers)
0 (Immunoglobulin G)
0 (Mitochondrial Proteins)
Entry Date(s):: Date Created: 20201112 Date Completed: 20210101 Latest Revision: 20210101
Update Code:: 20240105
PubMed Central ID:: PMC7661052
DOI:: 10.1371/journal.pone.0242164
PMID:: 33180817
: Czasopismo naukowe

Pełny tekst

Background and Objective: The relationship between antimitochondrial antibody (AMA) levels and the severity or prognosis of primary biliary cholangitis (PBC) is unclear. This study explored the clinical significance of serum IgG antimitochondrial M2 antibody (IgG-M2) levels.
Methods: From 2008 to 2017, a retrospective analysis was conducted with PBC patients who had available quantitative values of serum IgG-M2 levels obtained with ELISA based on triple expression hybrid clones. The patients were divided into two groups based on high and low concentrations of IgG-M2. Baseline parameters, the incidence of adverse events, and prognosis were compared.
Results: Among the 530 PBC patients, the levels of albumin, cholinesterase, hemoglobin, fibrinogen and triglycerides and the red blood cell count were significantly lower in the high-concentration group than in the low-concentration group (n = 263, 49.6%). The red cell distribution width (RDW) and levels of serum immunoglobulin (Ig) G, IgM and IgA were significantly higher in the high-concentration group than in the low-concentration group. Spearman's correlation analysis suggested that the correlation between the above baseline indicators and IgG-M2 levels was statistically significant but weak (r < 0.2, P < 0.05). In total, 203 patients were followed up, of whom 87 (42.9%) were in the high-concentration group. During the median follow-up period of 52 months (range: 28-75), 121 (59.6%) experienced hepatic decompensation, and 37 (18.2%) died or underwent liver transplantation. There was no significant difference in the incidence of complications or survival (log-rank test: P = 0.079) between the two groups. One year after ursodeoxycholic acid (UDCA) treatment, the two groups had similar responses. In addition, the levels of IgG-M2 did not fluctuate significantly during treatment.
Conclusion: IgG-M2 levels were not related to the disease severity, prognosis or efficacy of UDCA. The levels of IgG-M2 did not change significantly during treatment.
Competing Interests: The authors have declared that no competing interests exist.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja

Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.